Skip to main content

autologous kras g12d-specific hla-c*08:02-restricted tcr gene engineered t-lymphocytes nt-112

Generic: Autologous KRAS G12D-specific HLA-C*08:02-restricted TCR Gene Engineered T-lymphocytes NT-112

autologous kras g12d-specific hla-c*08:02-restricted tcr gene engineered t-lymphocytes nt-112: 1 clinical trial tracked.

autologous kras g12d-specific hla-c*08:02-restricted tcr gene engineered t-lymphocytes nt-112 evidence translation

What we can confirm

1 tracked trial

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about autologous kras g12d-specific hla-c*08:02-restricted tcr gene engineered t-lymphocytes nt-112, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 1 study sponsors
Clinical Trial Registry Records (1)

Open-label, Phase 1, Multi-Center Master Protocol to Evaluate the Safety and Preliminary Anti-Tumor Activity of TCR-engineered T Cells Recognizing KRAS Mutations in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT06218914Registry updated 2026-07-28·Phase 1·AZN
Recruiting

Primary endpoint: Part A (Dose Escalation): Evaluate the safety of KRAS TCRTs in subjects with unresectable, advanced, and/or metastatic solid tumors

Interventionalopen108 targetStarted 2024-03Completion 2043-1118 sites · United StatesAstraZeneca